Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001075265 | SCV001240880 | uncertain significance | Retinal dystrophy | 2017-08-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001234321 | SCV001406960 | uncertain significance | not provided | 2025-01-13 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 339 of the IMPG1 protein (p.Thr339Asn). This variant is present in population databases (rs112474181, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with IMPG1-related conditions. ClinVar contains an entry for this variant (Variation ID: 866895). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Dept Of Ophthalmology, |
RCV001075265 | SCV004704717 | benign | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Ambry Genetics | RCV004031189 | SCV004885621 | uncertain significance | not specified | 2024-02-05 | criteria provided, single submitter | clinical testing | The c.1016C>A (p.T339N) alteration is located in exon 10 (coding exon 10) of the IMPG1 gene. This alteration results from a C to A substitution at nucleotide position 1016, causing the threonine (T) at amino acid position 339 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |